Germany-based BioNTech and its Chinese partner Shanghai Fosun Pharmaceutical have agreed to provide an initial 100 million doses of the Mainz-headquartered company’s mRNA...
The European Medicines Agency (EMA) on Dec. 21 provisionally cleared EU-wide use of the Pfizer-BioNTech Covid-19 vaccine, which will be marketed under the brand name...
Facing scrutiny from the manufacturers, health ministers of some member states and the public, the European Medicines Agency (EMA) has moved the timetable to conclude...
The US Food and Drug Administration on Dec. 11 awarded an emergency use authorization (EUA) for the Pfizer-BioNTech mRNA-based Covid-19 vaccine. The green light followed...
In a move that was not on the world’s radar, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has become the first Western regulatory body to issue an...
As planned, US drugmaker Pfizer and German biotech BioNTech filed an Emergency Use Authorization (EUA) request with the US Food and Drug Administration (FDA) for their...
US drugmaker Pfizer and its German development partner BioNTech have reached a final agreement with the European Commission to supply 200 million doses of their mRNA...
Phase 3 clinical trials with the mRNA vaccine candidate BNT162b2 being developed by US pharma giant Pfizer and German biotech partner BioNTech have shown it to be more...
